MAKE WAY FOR THE FIRST ACTIVE HEMOSTATIC POWDER

MAKE WAY FOR THE FIRST ACTIVE HEMOSTATIC POWDER

14 FEBRUAR 2018

Euronext – Biom’up Announces a Financing Targeting a Total of €43m

Capital increase of an initial amount of €18m which may be increased to €20.7m by means of a public offering without preferential subscription rights and with a priority subscription period of three trading days as of right only

Proposed bond issue with stock warrants of an initial amount of €25m which may be increased to €35m for the benefit of investment funds managed by Athyrium Capital Management, a major US investor in the healthcare sector, which also agrees to take part in the capital increase

The proposed bond issue, which is subject to the Capital Increase achieving at least €15m of its initial amount, will enable the company to refinance the Kreos Capital loan of €8.2m (…)

 

Read more:  https://www.euronext.com/fr/node/739678

Alle news

Rechtliche Informationen: HEMOBLAST™ Bellows - Implantierbares Medizinprodukt der Klasse III für die Chirurgie, nur für den Gebrauch durch qualifizierte medizinische Fachkräfte vorgesehen, Erstattung abhängig vom jeweiligen Land.
Vor Gebrauch die Anweisungen auf der Verpackung sorgfältig durchlesen. CE0086: BSI - Hersteller: Biom’up SA Frankreich.